Analyzing GOI expression in divisions distinguished based on the Youden’s index regarding comorbidities number, the normalized expression level of EPAS1 and VEGFA differed significantly (p = 0.0133 and p < 0.0001, respectively) between controls and cancer patients, but only in group ≤ 1 was there comorbid disease presence, and in cancerous tissue they were lower for EPAS1 and higher for VEGFA (Supplementary Materials, Figure S1). This evidence concerns the gene EPAS1 and cancer.